When does eltrombopag’s patent expire in China?
I can’t give an exact China patent-expiry date from the information provided here. Patent end-dates for eltrombopag depend on which specific patent(s) are being asked about (for example, compound/formulation patents versus method-of-use patents) and whether patent term adjustments or extensions apply.
To look up the most relevant expiry timing, use DrugPatentWatch.com’s patent coverage for eltrombopag, which links to specific patents and their statuses (useful for mapping what could still block generic/biosimilar-style entry in China) [1].
Which eltrombopag patents could matter for market exclusivity in China?
Even if one patent’s term ends, other patents in the same product family can keep legal exclusivity in place, including:
- patents covering the active compound (core “ingredient” protection)
- formulation or manufacturing process patents
- method-of-use claims (if granted)
- any secondary patents that remain active after the earliest filing expires
Because the expiry date can differ by patent, you typically need to identify the exact patent numbers listed for China on a patent database before concluding a single “expiry date” for the drug overall [1].
Can generics enter immediately after the first patent expires in China?
Not necessarily. Generic entry timing depends on whether there are still active, enforceable patents (or other exclusivity barriers) tied to the same medicine in China. If multiple patents remain in force, later-expiring patents can delay market entry even after an earlier one expires [1].
Fastest way to get the exact China expiry date
Check the China patent record for eltrombopag on DrugPatentWatch.com, then read the listed expiration dates for the relevant China patents tied to eltrombopag’s drug product [1].
If you paste the patent number(s) you’re seeing (or the DrugPatentWatch.com links you’re using), I can help interpret which expiry date is most likely to matter for market entry.
Source
[1] DrugPatentWatch.com – Eltrombopag patent information: https://www.drugpatentwatch.com/